SAN FRANCISCO, CA / ACCESSWIRE / February 27, 2020 / Hagens Berman urges investors in Sasol ADRs (NYSE:SSL) who have suffered significant losses to submit their losses now. A securities class action has been filed, and certain investors may have valuable claims.

Class Period: Mar. 10, 2015 – Jan. 13, 2020

Lead Plaintiff Deadline: Apr. 6, 2020

Sign Up: www.hbsslaw.com/investor-fraud/SSL

Contact An Attorney Now: SSL@hbsslaw.com 844-916-0895

Sasol Limited (SSL) Securities Class Action:

According to the Complaint, Defendants misled investors by misrepresenting and failing to disclose that; (1) Sasol conducted insufficient due diligence into and did not account for multiple issues with, Sasol's Lake Charles chemical plant ("LCCP"), as well as its true cost; (2) construction and operation of the LCCP was plagued by control weaknesses, delays, rising costs, and technical issues; and (3) Sasol's top-level management exacerbated these issues by engaging in improper and unethical behavior concerning financial reporting for, and oversight of, the LCCP.

Investors began to learn the truth through a series of disclosures, including on May 22, 2019, when Sasol abruptly raised the project's cost estimate by $1 billion and disclosed an internal review into the project's costs and construction schedule. The company admitted to weaknesses in the project's integrated controls, as well as significant additional concerns related to the project's forecasting process.

Then, on Oct. 27, 2019, Sasol terminated its co-CEOs following an internal probe showing that the Lake Charles project management team acted inappropriately, lacked experience, and was overly focused on maintaining cost and schedule estimates instead of providing accurate information.

Finally, on Jan. 13, 2020, Sasol disclosed an explosion and fire at its Lake Charles project's low-density polyethylene unit, requiring the company to shut down the unit.

Each of these disclosures caused the price of Sasol ADRs to decline sharply.

"We're focused on investors' losses and proving Sasol misled investors about the Lake Charles project's cost, timing, and internal controls," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased Sasol ADRs and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Sasol should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SSL@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers, and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news, visit our newsroom or follow us on Twitter at @classactionlaw.

CONTACT:
Reed Kathrein
P: 844-916-0895
E: SPR@hbsslaw.com

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 578304

SAN FRANCISCO, CA / ACCESSWIRE / February 27, 2020 / Hagens Berman urges investors in Geron Corporation (NASDAQ:GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. The Lead Plaintiff deadline is March 23, 2020 and certain investors may have valuable claims.

Class Period: Mar. 19, 2018 – Sept. 26, 2018

Lead Plaintiff Deadline: Mar. 23, 2020

Sign Up: www.hbsslaw.com/investor-fraud/GERN

Contact An Attorney Now: GERN@hbsslaw.com 844-916-0895

Geron Corporation (GERN) Securities Class Action:

The complaint alleges that Geron misled investors about the results of a clinical study of Imetelstat, the Company's core drug intended to treat certain bone marrow cancers. According to the complaint, Geron touted its development of Imetelstat in partnership with Janssen Biotech Inc. ("Janssen"), a division of Johnson & Johnson, while allegedly concealing that Imetelstat provided minimal benefits to patients with myelofibrosis cancer.

The truth emerged on Sept. 27, 2018, when Geron disclosed disappointing efficacy data and that its deep-pocketed commercial partner, Janssen, terminated its partnership with Geron.

This news caused the price of Geron's shares to decline sharply.

"We're focused on investors' losses and proving Geron misled investors by promoting Imetelstat while concealing material efficacy data," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Geron Corporation and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Geron Corporation should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email GERN@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers, and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

CONTACT:
Reed Kathrein
P: 844-916-0895
E: SPR@hbsslaw.com

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 578303

VANCOUVER, BC / ACCESSWIRE / February 27, 2020 / NHS Industries Ltd. (CSE:NHS) (the "Company" or "NHS") announced that it has acquired all of the issued and outstanding shares of Plenty-Full Food Services Ltd. ("Plenty-Full"), a privately held meal preparation start-up company based in Richmond, BC. The acquisition will accelerate the Company's strategic plans to expand into the food services industry and to build a food facility from its Langley farm property.

The acquisition transaction has been completed by way of a three‐cornered amalgamation under the BC Business Corporations Act, whereby 1237696 BC Ltd., a wholly‐owned subsidiary of the Company, will amalgamate with Plenty-Full. All of the issued and outstanding common shares of Plenty-Full will be exchanged on the basis of three (3) common shares of NHS, for each one (1) Plenty-Full common share. Existing NHS and Plenty-Full shareholders will own approximately 53% and 47% of the resulting company, respectively. The transaction has been approved by the Boards of Directors of NHS and Plenty-Full and the shareholders of Plenty-Full.

The Company also announced that it is conducting a private placement offering of up to 20,000,000 units at a price of $0.05 per unit for gross proceeds of up to $1,000,000. Each unit shall consist of one common share in the capital of the Company and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share of the Company at a price of $0.10 per warrant share for a period of 24 months following completion of the financing. subject to a number of conditions, including, without limitation, receipt of all regulatory approvals. All securities issued pursuant to the offering will be subject to a statutory hold period of four months and one day, and subject to regulatory approval. The Company intends to use the net proceeds of the offering for general corporate purposes.

The Company is also pleased to announce that Robert Nygren, who was recently appointed to the Board of Directors of NHS, will now also serve as the CEO effective immediately. Carman Parente will continue to act as the President of NHS. In addition, Ming Chiang, the past President & CEO of Plenty-Full, has been appointed to the Board of Directors and will assume the position of Chief Strategy Officer of NHS.

NHS further announced today that pursuant to the Company's Stock Option Plan, an aggregate of 3,750,000 stock options have been granted to certain consultants as incentive stock options at an exercise price of $0.05 per share. The options are exercisable for a period of five years, ending on February 26, 2025.

About NHS Industries Ltd.

NHS is an agri-food holdings company focused on innovative products and technologies in the food services industry.

For further information about NHS, please consult the Company's profile on SEDAR at www.sedar.com.

On Behalf of the Board of Directors

Robert Nygren
Chief Executive Officer
info@nhsindustries.ca
(888) 202-5153

###

WWW.NHSINDUSTRIES.CA

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to completion of planned improvements on schedule and on budget, the availability of financing needed to complete the Company's planned improvements on commercially reasonable terms, delays in obtaining statutory and/or regulatory approval for production plans, the ability to mitigate the risk of loss through appropriate insurance policies, among others. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

SOURCE: NHS Industries Ltd.

ReleaseID: 578310

NEW YORK, NY / ACCESSWIRE / February 27, 2020 / Rosen Law Firm, a global investor rights law firm, announces it has filed a class-action lawsuit on behalf of purchasers of the securities of Crown Castle International Corp. (NYSE:CCI, CCI-PA) between February 26, 2018 and February 26, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Crown Castle investors under the federal securities laws.

To join the Crown Castle class action, go to http://www.rosenlegal.com/cases-register-1790.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Crown Castle's internal control over financial reporting and disclosures controls and procedures were ineffective and materially weak; (2) Crown Castle's financial accounting and reporting was not in accordance with GAAP; (3) Crown Castle's net income, adjusted EBITDA, and adjusted funds from operations were inflated; (4) Crown Castle would need to restate its financial statements for the years ended December 31, 2018 and 2017, and unaudited financial information for the quarterly and year-to-date periods in the year ended December 31, 2018 and for the first three quarters in the year ended December 31, 2019; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class-action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 27, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1790.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll-free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:
Laurence Rosen, Esq.
lrosen@rosenlegal.com
Phillip Kim, Esq.
pkim@rosenlegal.com
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: Rosen Law Firm PA

ReleaseID: 578300

SAN FRANCISCO, CA / ACCESSWIRE / February 27, 2020 / Hagens Berman urges investors in Spirit AeroSystems Holdings, Inc. (NYSE:SPR) who have suffered significant losses to submit their losses now. A securities class action has been filed, and certain investors may have valuable claims.

Class Period: Oct. 31, 2019 – Jan. 29, 2020

Lead Plaintiff Deadline: Apr. 10, 2020

Sign Up: www.hbsslaw.com/investor-fraud/SPR

Contact An Attorney Now: SPR@hbsslaw.com 844-916-0895

Spirit AeroSystems Holdings, Inc. (SPR) Securities Class Action:

The Complaint alleges Defendants misled investors by misrepresenting and failing to disclose that (1) Spirit lacked effective internal controls over financial reporting; (2) the Company was violating its established accounting principles related to potential contingent liabilities; and, as a result, (3) Defendants' financial reporting and statements about Spirit's business, operations, and prospects were misleading.

On Jan. 30, 2020, investors began to learn the truth when Spirit announced the abrupt departures of Chief Financial Officer Jose Garcia and Principal Accounting Officer John Gilson. The Company explained "[i]n December 2019, the Company received information through its established compliance processes that led the Company to commence a review of its accounting process compliance" and "[a]s a result of the review, which is ongoing, the Company determined that it did not comply with its established accounting processes with respect to certain potential contingent liabilities received by the Company after the end of the third quarter of 2019."

This news drove the price of Spirit shares sharply lower on Jan. 30, 2020.

"We're focused on investors' losses and proving Spirit concealed certain liabilities to appear more liquid," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Spirit and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Spirit should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SPR@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

CONTACT:
Reed Kathrein
P: 844-916-0895
E: SPR@hbsslaw.com

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 578305

BALA CYNWYD, PA / ACCESSWIRE / February 27, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

Telaria, Inc. (NYSE:TLRA)

Under the terms of the agreement, Telaria shareholders will receive only 1.082 shares of Rubicon common stock for each share of Telaria stock that they hold. The investigation concerns whether the Telaria Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Rubicon is underpaying for the Company. For example, Telaria was trading above the original implied deal price as of September 2019. Additionally, at least one analyst following Telaria has set a target price of $14.00 a share.

Additional information can be found at http://www.brodskysmith.com/cases/telaria-inc-nyse-tlra/, or call 877-534-2590. No cost or obligation to you.

Legg Mason, Inc. (NYSE:LM)

Under the terms of the agreement, Legg Mason shareholders will receive only $50.00 for each share of Legg Mason stock they own. The investigation concerns whether the Legg Mason Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Franklin Resources is underpaying for the Company.

Additional information can be found at http://www.brodskysmith.com/cases/legg-mason-inc-nyse-lm/, or call 877-534-2590. No cost or obligation to you.

CINCINNATI BELL, INC. (NYSE:CBB)

Under the terms of the agreement, Cincinnati Bell shareholders will receive only $10.50 for each share of Cincinnati Bell common stock owned. The investigation concerns whether the Cincinnati Bell Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Brookfield Infrastructure is underpaying for the Company. For example, the deal consideration is below the Company's 52-week high of $11.00.

Additional information can be found at http://www.brodskysmith.com/cases/cincinnati-bell-inc-nyse-cbb/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 578210

BALA CYNWYD, PA / ACCESSWIRE / February 27, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of GAIN Capital Holdings. Inc. ("GAIN" or the "Company") (NYSE:GCAP) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the proposed acquisition of the Company by INTL FCStone Inc. ("INTL"). Under the terms of the agreement, GAIN shareholders will receive only $6.00 for each share of GAIN stock that they own.

The investigation concerns whether the GAIN Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether INTL is underpaying for the Company. For example, the deal price is significantly lower than the 52-week high of $7.40 for the Company's shares.

If you own shares of GAIN stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://www.brodskysmith.com/cases/gain-capital-holdings-inc-nyse-gcap/, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Law office of Brodsky & Smith, LLC

ReleaseID: 578177

VANCOUVER, BC / ACCESSWIRE / February 27, 2020 / Exro Technologies Inc. (CSE:XRO; OTCQB:EXROF) (the "Company" or "Exro") is pleased to announce that, further to its news releases dated February 6 and 14, 2020, it has closed the second and final tranche of its oversubscribed non-brokered private placement financing and raised $4,299,590 through the issuance of 12,284,545 common shares ("Shares") at a price of $0.35 per Share (the "Offering"). In the second tranche, 2,253,897 Shares were issued for gross proceeds of $788,864.

The Company has paid Finder's fee consisting of 7% cash and has issued compensation warrants equal to 7% of the number of Shares issued to investors introduced to the Company by the Finder (each a "Compensation Warrant"). Each Compensation Warrant is exercisable to acquire one common share for a period of 12 months from the closing at an exercise price of $0.42 per share.

The Shares will be subject to a four-month hold period from the date of issuance, pursuant to relevant prospectus or registration exemptions in accordance with applicable laws.

The net proceeds raised from the sale of this Offering will be used by the Company to fund development of the Company's current and new technology programs, the buildout of its new Calgary Innovation Centre, working capital and general corporate purposes.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

CONTACT:

Canada:

Jake Bouma
Intrynsyc Capital Corp.
604-317-3936

United States:

Vic Allgeier
TTC Group Inc.
646-841-4220
Email: info@exro.com

About Exro Technologies Inc.

Exro facilitates the transition to clean energy by providing products and services to manufacturers to increase the efficiency and reliability of power systems, including electric motors, generators and batteries. Exro's patented technology enhances energy systems by dynamically sensing and adapting variable inputs and optimally matching them to desired outputs, creating measurable performance gains and extended lifespan. The widespread applications of the technology applied to optimizing the performance of electric vehicles, UAVs, and ship drives, as well as pumps, industrial motors, and energy capture from wind and tides.

For more information visit our website at www.exro.com.

ON BEHALF OF THE BOARD OF DIRECTORS

Sue Ozdemir, CEO

Forward-Looking Statements

Certain statements contained in this News Release constitute forward-looking statements. When used in this document, the words "believe", "may", "would", "could", "will" and similar expressions, as they relate to the Company or its management are intended to identify forward-looking statements. More particularly and without limitation, this news release contains forward-looking statements and information concerning the Company's intention to commercialize its product in the near term. Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual performance or achievements to vary from those described herein. Should one or more of these factors or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. The Company does not assume any obligation to update these forward-looking statements, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

SOURCE: Exro Technologies Inc.  

ReleaseID: 578302

NEW YORK, NY / ACCESSWIRE / February 27, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)
Class Period: May 8, 2019 to January 9, 2020
Lead Plaintiff Deadline: March 16, 2020

Throughout the class period, Portola Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Portola's internal control over financial reporting regarding reserve for product returns was not effective; (2) Portola was shipping longer-dated product with 36-month shelf life; (3) Portola had not established adequate reserve for returns of prior shipments of short-dated product; (4) as a result, Portola was reasonably likely to need to "catch up" on accounting for return reserves; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in PTLA: http://www.kleinstocklaw.com/pslra-1/portola-pharmaceuticals-inc-loss-submission-form?id=5539&from=1

Geron Corporation (NASDAQ:GERN)
Class Period: March 19, 2018 to September 26, 2018
Lead Plaintiff Deadline: March 23, 2020

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

Learn about your recoverable losses in GERN: http://www.kleinstocklaw.com/pslra-1/geron-corporation-et-al-loss-submission-form?id=5539&from=1

Luckin Coffee Inc. (NASDAQ:LK)
Class Period: November 13, 2019 to January 31, 2020
Lead Plaintiff Deadline: April 13, 2020

The complaint alleges that throughout the class period Luckin Coffee Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) certain of Luckin's financial performance metrics, including per-store per-day sales, net selling price per item, advertising expenses, and revenue contribution from "other products" were inflated; (ii) Luckin's financial results thus overstated the Company's financial health and were consequently unreliable; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in LK: http://www.kleinstocklaw.com/pslra-1/luckin-coffee-inc-loss-submission-form?id=5539&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 578301

Palladium reaches all-time record of $2,911.70 per ounce, today

ADDISON, TX / ACCESSWIRE / February 27, 2020 / Today, palladium reached its all-time record high of $2,911.70 per ounce. Dillon Gage, the world leader in physical precious metals, explains why palladium is worth a lot more than its weight in gold.

The sky seems to be the limit for palladium, which is now one of the most valuable precious metals — far surpassing the prices of gold, silver and platinum.

"Palladium is likely to cross the $3,000 an ounce threshold any day now," said Terry Hanlon, president of Dillon Gage.

The metal's latest record, achieved today, is $2,911.70 per ounce. That means that an ounce of palladium is now more than $1,000 more expensive than an ounce of gold on international markets.

Palladium is up almost 49% — or more than $963 — since the start of 2020, and that's after rallying 54% in 2019. As long as a year ago — when palladium was almost $1,600 cheaper than it is now — The Wall Street Journal reported that thieves were stealing the metal right out of car engines.

So, what is palladium and why is it heading for the stratosphere?

It's all about the quest to save the planet.

The silvery-white metal, palladium, is a key component in catalytic converters – devices that control the pollution expelled from gasoline-fueled cars and trucks because it resists corrosion. About 85% of the world's palladium ends up in the exhaust systems of vehicles, and demand for cars, particularly from new drivers in places like China, is booming.

Palladium is also used in jewelry and some dental fillings and crowns, electronics, technological processes, photography and as an investment.

Supplies are tight, too. Most of the metal is mined in Russia and South Africa and it's actually a byproduct of mines that extract other metals, including platinum and nickel. So miners can't easily decide to just start producing more palladium.

While a Russian company — MMC Norilsk Nickel PJSC — is the world's largest palladium producer, it's the South African miners that have helped keep prices volatile in recent months. In December, for example, mining companies had to halt operations for days because of power outages after the local utility, Eskom, imposed rolling blackouts to keep up with demand. Labor disputes also crop up and can limit production, helping to drive up prices.

With demand for new, cleaner-burning cars exploding and supplies so precarious, palladium is well positioned to extend its historic rally.

Dillon Gage is the world leader in physical precious metals trading and technology serving dealers, financial institutions, banks and brokerage houses around the globe. For more information on Dillon Gage Metals, please visit www.dillongage.com or call 800-375-4653. For a weekly update on precious metals, follow Dillon Gage's blog at www.DillonGage.com/blog.

###

About Dillon Gage Metals

Dillon Gage is the world leader in physical precious metals trading and technology serving dealers, financial institutions, banks and brokerage houses around the globe. Since 1976, Dillon Gage has led the way in innovation, advanced trading tools, technology and intellect. The firm is one of a handful of firms who are authorized purchasers of bullion (including coins, rounds and bars) for all major world mints and maintains inventory in over 20 countries. Dillon Gage's integrated products and services include numismatics, bullion and electronic trading of precious metals and fulfillment, API integration, physical gold tracked by blockchain technology, refining and storage. The firm operates: FizTrade Online Trading, IRAConnect, Dillon Gage Refining and International Depository Services Group, a privately-owned subsidiary of Dillon Gage Metals, with locations in Delaware, Texas and Ontario. Dillon Gage's philanthropic arm, HELPS International, provides relief, development and educational opportunities to Guatemala. Learn more about Dillon Gage at DillonGage.com.

Media Contact for Dillon Gage:

Jo Trizila, TrizCom Public Relations
972-247-1369 (Office)
214-232-0078 (Cell/Text)
Jo@TrizCom.com

SOURCE: Dillon Gage Metals

ReleaseID: 578296